PE20231106A1 - Inhibidores de apol1 y metodos para usar los mismos - Google Patents

Inhibidores de apol1 y metodos para usar los mismos

Info

Publication number
PE20231106A1
PE20231106A1 PE2023000722A PE2023000722A PE20231106A1 PE 20231106 A1 PE20231106 A1 PE 20231106A1 PE 2023000722 A PE2023000722 A PE 2023000722A PE 2023000722 A PE2023000722 A PE 2023000722A PE 20231106 A1 PE20231106 A1 PE 20231106A1
Authority
PE
Peru
Prior art keywords
apol1
inhibitors
methyltriazol
piran
spiro
Prior art date
Application number
PE2023000722A
Other languages
English (en)
Inventor
Jun Myun Ahn
Samantha Angle
Michael Aaron Brodney
Jingrong Cao
John E Cochran
Jon H Come
Leslie A Dakin
Elena Dolgikh
Brad D Maxwell
Suganthini S Nanthakumar
Hardwin O’Dowd
Jessica Howard Olsen
Timothy J Senter
Akira Joseph Shimizu
Steven David Stone
Haoxuan Wang
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of PE20231106A1 publication Critical patent/PE20231106A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A COMPUESTOS ESPIROHETEROCICLOS DE FORMULA (I) DONDE LOS RADICALES X1, X2, R1, R3a, R3b, R4, R5, k Y m SON TAL COMO SE DESCRIBEN EN EL PRESENTE DOCUMENTO. SON COMPUESTOS PREFERIDOS: (2'S,6'S,7S)-2-CLORO-2'-METIL-6'-(1-METILTRIAZOL-4-IL)ESPIRO[4,5-DIHIDROTIENO[2,3-C]PIRAN-7,4'-PIPERIDINA]; (2'S,6'S,7S)-2'-METIL-6'-(1-METILTRIAZOL-4-IL)-2-(TRIFLUOROMETIL)ESPIRO[4,5-DIHIDROTIENO[2,3-C]PIRAN-7,4'-PIPERIDINA]; [(2'S,6'S,7S)-2'-METIL-6'-(1-METILTRIAZOL-4-IL)-2-(TRIFLUOROMETIL)ESPIRO[4,5-DIHIDROTIENO[2,3-C]PIRAN-7,4'-PIPERIDIN]-3-IL]METANOL; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA APOLIPOPROTEINA L1 (APOL1) SIENDO UTILES EN EL TRATAMIENTO DE GLOMERULOESCLEROSIS SEGMENTARIA FOCAL (FSGS) Y ENFERMEDAD RENAL NO DIABETICA.
PE2023000722A 2020-08-26 2021-08-26 Inhibidores de apol1 y metodos para usar los mismos PE20231106A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063070705P 2020-08-26 2020-08-26
PCT/US2021/047754 WO2022047031A1 (en) 2020-08-26 2021-08-26 Inhibitors of apol1 and methods of using same

Publications (1)

Publication Number Publication Date
PE20231106A1 true PE20231106A1 (es) 2023-07-19

Family

ID=77822053

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023000722A PE20231106A1 (es) 2020-08-26 2021-08-26 Inhibidores de apol1 y metodos para usar los mismos

Country Status (20)

Country Link
US (1) US11866446B2 (es)
EP (1) EP4204423A1 (es)
JP (1) JP2023539194A (es)
KR (1) KR20230057386A (es)
CN (1) CN116547287A (es)
AR (1) AR123355A1 (es)
AU (1) AU2021333776A1 (es)
BR (1) BR112023003423A2 (es)
CA (1) CA3190609A1 (es)
CL (1) CL2023000536A1 (es)
CO (1) CO2023003026A2 (es)
CR (1) CR20230132A (es)
DO (1) DOP2023000042A (es)
EC (1) ECSP23020167A (es)
IL (1) IL300298A (es)
MX (1) MX2023002269A (es)
PE (1) PE20231106A1 (es)
TW (1) TW202227456A (es)
UY (1) UY39395A (es)
WO (1) WO2022047031A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
KR20220151634A (ko) 2020-03-06 2022-11-15 버텍스 파마슈티칼스 인코포레이티드 Apol-1 의존성 국소 분절성 사구체경화증을 치료하는 방법
CA3190609A1 (en) 2020-08-26 2022-03-03 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20230119114A1 (en) * 2021-08-26 2023-04-20 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitors and methods of using same
US11976067B2 (en) 2022-01-18 2024-05-07 Maze Therapeutics, Inc. APOL1 inhibitors and methods of use
WO2023154344A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
US6518423B1 (en) 1996-08-09 2003-02-11 Eisai Co., Ltd. Benzopiperidine derivatives
WO2001017965A2 (en) 1999-09-07 2001-03-15 Syngenta Participations Ag Cyanopiperidines as pesticides
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
AU2002211828A1 (en) 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
WO2003104180A1 (en) 2002-06-05 2003-12-18 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
EP1723105B1 (en) 2004-03-03 2013-05-15 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
EP2086935A1 (de) 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
RU2009123133A (ru) 2006-12-22 2011-01-27 Ф.Хоффманн-Ля Рош Аг (Ch) Производные спиро-пиперидина
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
CN101801965B (zh) 2007-08-17 2014-07-30 株式会社Lg生命科学 作为细胞坏死抑制剂的吲哚化合物
US9101616B2 (en) 2009-05-29 2015-08-11 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
SI2501704T1 (sl) 2009-11-16 2013-11-29 Eli Lilly Company Spojine spiropiperidina kot antagonisti oral-1 receptorja
UA107943C2 (en) 2009-11-16 2015-03-10 Lilly Co Eli Compounds of spiropiperidines as antagonists of the orl-1 receptors
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
WO2015048301A1 (en) 2013-09-26 2015-04-02 Pharmakea, Inc. Autotaxin inhibitor compounds
CA2959437C (en) 2014-08-27 2018-03-06 The Governing Council Of The University Of Toronto Cannabinoid type 1 receptor modulators
US10654838B2 (en) 2014-10-08 2020-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Aminopyridine compounds useful as inhibitors of protein prenylation
US10407428B2 (en) 2014-11-21 2019-09-10 Esteve Pharmaceuticals, S.A. Spiro-isoquinoline-1,4′-piperidine compounds having multimodal activity against pain
MX2018002402A (es) 2015-08-27 2018-04-11 Pfizer Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
WO2017137334A1 (en) 2016-02-08 2017-08-17 F. Hoffmann-La Roche Ag Spiroindolinones as ddr1 inhibitors
CA3103020A1 (en) 2018-04-30 2019-11-07 The Trustees Of Indiana University Compounds for modulating ddah and adma levels, as well as methods of using thereof to treat disease
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2020186220A1 (en) 2019-03-13 2020-09-17 Immunophage Biomedical Co., Ltd. Compounds as inhibitors of macrophage migration inhibitory factor
CN115087440A (zh) 2019-12-19 2022-09-20 卡斯玛治疗公司 Trpml调节剂
CA3168909A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
WO2021158666A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
KR20220151634A (ko) 2020-03-06 2022-11-15 버텍스 파마슈티칼스 인코포레이티드 Apol-1 의존성 국소 분절성 사구체경화증을 치료하는 방법
WO2021216665A1 (en) 2020-04-22 2021-10-28 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications
CA3182373A1 (en) 2020-05-07 2021-11-11 Rambam Med-Tech Ltd. Composition for use in the treatment of apol1-associated disease
TW202214601A (zh) 2020-06-12 2022-04-16 美商維泰克斯製藥公司 Ａｐｏｌ１抑制劑之固體形式及其使用方法
AU2021286666A1 (en) 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and use of the same
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CA3190609A1 (en) 2020-08-26 2022-03-03 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20230119114A1 (en) 2021-08-26 2023-04-20 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitors and methods of using same

Also Published As

Publication number Publication date
EP4204423A1 (en) 2023-07-05
MX2023002269A (es) 2023-05-16
TW202227456A (zh) 2022-07-16
CL2023000536A1 (es) 2023-09-08
UY39395A (es) 2022-03-31
DOP2023000042A (es) 2023-07-09
ECSP23020167A (es) 2023-12-29
AU2021333776A1 (en) 2023-03-16
CA3190609A1 (en) 2022-03-03
CO2023003026A2 (es) 2023-03-17
IL300298A (en) 2023-04-01
AR123355A1 (es) 2022-11-23
KR20230057386A (ko) 2023-04-28
US11866446B2 (en) 2024-01-09
CN116547287A (zh) 2023-08-04
WO2022047031A1 (en) 2022-03-03
BR112023003423A2 (pt) 2023-03-21
US20220106327A1 (en) 2022-04-07
JP2023539194A (ja) 2023-09-13
CR20230132A (es) 2023-06-27

Similar Documents

Publication Publication Date Title
PE20231106A1 (es) Inhibidores de apol1 y metodos para usar los mismos
RU2470023C2 (ru) 1-цианоциклопропильные производные в качестве ингибиторов катепсина к
AR051997A1 (es) Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos
CR9022A (es) Derivados de sulfonamida novedosos como moduladores de receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
AR060287A1 (es) Compuesto de 5,6 dihidro-3h-pirrolo[1,2,3-de]quinoxalini-3-ona, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuesto intermediario util para su preparacion
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
HUP0303432A2 (hu) Szubsztituált piridoindolok mint szerotonin agonisták és antagonisták, és a vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AR022860A1 (es) Derivados de camptotecina que poseen actividad antitumoral
AR061918A1 (es) Compuesto biciclico que contiene nitrogeno, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
ECSP067098A (es) Compuestos y metodos para el tratamiento de dislipidemia
UY27740A1 (es) Nuevos compuestos
UY28510A1 (es) Compuestos quimicos
AR050530A1 (es) Derivados de heteroaril sulfamida benzo-fusionada utiles como agentes anticonvulsivos
CU23779B7 (es) Compuestos de pirazolina y su uso y composiciones farmacéuticas
PE20030431A1 (es) DERIVADOS QUINUCLIDINAS COMO AGONISTAS DEL RECEPTOR NICOTINICO DE LA ACETILCOLINA TIPO a7
UY28526A1 (es) Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
ECSP077323A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
DOP2016000045A (es) Compuestos de benzoxaborol tricíclicos y usos de los mismos
PE20151251A1 (es) Derivados [5,6] biciclicos de imidazo pirimidona con actividad sobre enzimas lp-pla2
UY28360A1 (es) Nuevos compuestos
AR059501A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
BRPI0721113A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios
ECSP056247A (es) Triazolopirimidinas